ReviewCurrent treatment options in oncology2022
Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- The mechanism of malignant progression in extramammary Paget's disease (EMPD): hallmarks of EMPD.Medical molecular morphology · 2026Review
- [Treatment options in rare urological tumors: potential of molecular tumor boards].Urologie (Heidelberg, Germany) · 2026Review
- Melanoma microsatellites exhibit a metastatic signature by spatial transcriptomics and overexpress mediators of immune evasion.Virchows Archiv : an international journal of pathology · 2025Article
- One Man's Meat Is Another Man's Poison: High Incidence of Severe Cutaneous Drug Reactions Induced by Enfortumab Vedotin.European urology open science · 2025Article
- Recent advances in theranostics and oncology PET: emerging radionuclides and targets.Annals of nuclear medicine · 2025Review
- A novel SOX6 + melanoma cell subtype promotes early microsatellite invasion in Asian acral melanoma through fatty acid transport disorder.Journal of experimental & clinical cancer research : CR · 2025Article
- The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025Review
- Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer.Molecular diagnosis & therapy · 2025Review
- KS-NailMel-1: a novel cell line of nail apparatus melanoma.Human cell · 2025Article
- Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2.Current issues in molecular biology · 2025Article
- A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan.Scientific reports · 2025Article
- Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond.Therapeutic advances in medical oncology · 2025Review
- A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection.International cancer conference journal · 2024Article
- FOXM1: a new therapeutic target of extramammary Paget disease.Scientific reports · 2024Article
- KS-cSCC-1 and KS-cSCC-2: two novel cutaneous squamous cell carcinoma cell lines established from Japanese patients.Frontiers in medicine · 2024Article
- Therapeutic prospects of nectin-4 in cancer: applications and value.Frontiers in oncology · 2024Review
- Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.International journal of molecular sciences · 2023Article
- Article
- Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment.Cancers · 2023Article
- Nail Apparatus Melanoma: Current Management and Future Perspectives.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementNectin-4 is a tumor-associated antigen that is highly expressed on various cancer cells, and it has been further proposed to have roles in tumor development and propagation ranging from cellular proliferation to motility and invasion. Nectin-4 blockade reduces tumor proliferation and induces apoptosis in several malignancies. Nectin-4 has been used as a potential target in antibody-drug conjugate (ADC) development. Enfortumab vedotin, an ADC against Nectin-4, has demonstrated efficacy against solid tumor malignancies. Enfortumab vedotin has received US Food and Drug Administration approval for treating urothelial cancer. Furthermore, the efficacy of ADCs against Nectin-4 against solid tumors other than urothelial cancer has been demonstrated in preclinical studies, and clinical trials examining the effects of enfortumab vedotin are ongoing. Recently, Nectin-4 was reported to be highly expressed in several skin cancers, including malignant melanoma, cutaneous squamous cell carcinoma, and extramammary Paget's disease, and involved in tumor progression and survival in retrospective studies. Nectin-4-targeted therapies and ADCs against Nectin-4 could therefore be novel therapeutic options for skin cancers. This review highlights current knowledge on Nectin-4 in malignant tumors, the efficacy of enfortumab vedotin in clinical trials, and the prospects of Nectin-4-targeted agents against skin cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.